Casma Therapeutics to Present at Oppenheimer Rare & Orphan Disease Summit

May 14, 2021

CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) — Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Chief Executive Officer, Keith Dionne, Ph.D., will present a company overview at the upcoming Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 8:15 a.m. ET.

About Casma Therapeutics
Casma Therapeutics is harnessing autophagy by developing a novel degradation technology to open new target areas for drug discovery and development that will profoundly impact the lives of patients. Autophagy is a conserved cellular process that contributes to overall organismal health, but when autophagy is perturbed, inefficient autophagic flux contributes to numerous diseases. By selectively boosting autophagy and degradation of disease targets in the lysosome, Casma expects to be able to arrest or reverse the progression of several diseases such as neurodegeneration, metabolic disorders, inflammation and muscle degeneration. For more information, please visit www.casmatx.com.

Contact for Investors and Media

Courteney Backstrom
Casma Therapeutics, Inc.
cbackstrom@casmatx.com
857-777-4248

Back to news & media

Keep reading:

News April 17, 2024
Casma Therapeutics to Participate at 23rd Annual Needham Virtual Healthcare Conference and at UBS Virtual Targeted Protein Degradation Day

CAMBRIDGE, Mass., April 17, 2024 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy/lysosomal system to provide innovative new medicines, today announced that Frank Gentile, PhD, Chief Executive Officer, presented and participated in one-on-one meetings at the 23rd Annual Needham Virtual Healthcare Conference on April 5, 2024. Frank Gentile, PhD, will also attend and participate in […]
News February 28, 2024
Casma Therapeutics to Present at the Gordon Research Conference on Autophagy in Stress, Development, and Disease

CAMBRIDGE, Mass., February 28, 2024– Casma Therapeutics, Inc., a biotechnology company engaging the autophagy/lysosomal system to provide innovative new medicines, today announced that Leon Murphy, Ph.D., Chief Scientific Officer and Dan Baird Ph.D., Vice President, Molecular Discovery will participate in the Gordon Research Conference on Autophagy in Stress, Development, and Disease in Lucca, Italy. Dr. […]